On August 11, 2021 BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, reported the acceptance of all five abstracts submitted to the American Association for Cancer Research (AACR) (Free AACR Whitepaper) for presentation at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Bridgene Biosciences, AUG 11, 2021, View Source [SID1234586356]). The poster presentations will highlight BridGene’s proprietary small molecule discovery platform, IMTAC (Isobaric Mass Tagged Affinity Characterization), BridGene’s latest discovery of therapeutic candidates, and the identification of new targets for approved small molecule drugs. The conference will take place virtually October 7–10, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased that our latest developments through our chemoproteomic platform, IMTAC, will be the subject of five poster presentations at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC," stated Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences. "Our work at BridGene has the potential to address multiple therapeutic areas, which our five posters will illustrate. Overall, the posters describe our IMTAC platform and its capabilities, the discovery of novel small molecule inhibitors, and the identification of previously unknown targets for approved small molecule drugs. This conference, as part of AACR (Free AACR Whitepaper), is one of the most prominent events addressing drug discovery and molecular targets, and we are delighted to have the opportunity to demonstrate BridGene’s technology."
Information about the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC conference may be accessed here. According to AACR (Free AACR Whitepaper)’s Presentation and Publication Information, abstract titles will be released to the public on September 30, 2021, on the AACR (Free AACR Whitepaper) virtual platform.
About AACR (Free AACR Whitepaper)
The American Association for Cancer Research (AACR) (Free AACR Whitepaper) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Through its programs and services, the AACR (Free AACR Whitepaper) fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.